Früh, M.; Panje, C.M.; Reck, M; Blackhall, F; Califano, R; Cappuzzo, F; Besse, B; Novello, S; Garrido, P; Felip, E; O'Brien, M; Paz Ares, L; de Marinis, F; Westeel, V; De Ruysscher, D; Putora, P.M. (2020). Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. Lung cancer, 146, pp. 6-11. Elsevier 10.1016/j.lungcan.2020.03.024
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
1-s2.0-S0169500220303548-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (780kB) |
OBJECTIVES
Stage IV small cell lung cancer (SCLC) is associated with short survival and progression after first-line systemic therapy frequently occurs within months. Although topotecan is approved for second-line treatment, its efficacy is limited, and treatment heterogeneity exists.
MATERIAL AND METHODS
The decision-making patterns for second line treatment of 13 European medical oncologists with expertise in SCLC were analyzed.
RESULTS
The two criteria most relevant to decision-making were the performance status and the interval of recurrence since first-line treatment. With an interval of less than 3 months since the end of first-line chemotherapy, 62 % of the experts recommended cyclophosphamide, doxorubicin and vincristine (CAV) for fit patients and 54 % recommended topotecan for unfit patients. For an interval of more than 6 months, a clear consensus for a re-challenge with a platinum doublet was achieved (92 %). However, there was no consensus on the second-line therapy with an interval of 3-6 months since the end of first-line therapy.
CONCLUSION
Real world practice may differ from recommendations in general guidelines and cannot always be directly derived from trial results as other factor such as habits, patient's preference, convenience or costs have to be factored in.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology 04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology |
UniBE Contributor: |
Früh, Martin, Panje, Cédric, Putora, Paul Martin |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0169-5002 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Beatrice Scheidegger |
Date Deposited: |
24 Jun 2020 17:39 |
Last Modified: |
05 Dec 2022 15:39 |
Publisher DOI: |
10.1016/j.lungcan.2020.03.024 |
PubMed ID: |
32485661 |
Uncontrolled Keywords: |
Decision making Objective consensus Second-line chemotherapy Small cell lung cancer (SCLC) |
BORIS DOI: |
10.7892/boris.144508 |
URI: |
https://boris.unibe.ch/id/eprint/144508 |
Actions (login required)
 |
Edit item |